摘要
γ-氨基丁酸A型受体(GABAAR),包括其α5亚单位(α5GABAAR)主要在海马体中被发现。在海马体中,它们调停一种强直氯化物泄漏电流,在GABA能抑制性突触电流中构成减速部分。它们对海马神经元兴奋的抑制作用至少部分地解释了为什么改变α5GABAAR的活动水平会影响认识,学习和记忆。这些受体作为一些临床情况潜在的治疗靶点被涉及。这些临床情况包括老年痴呆、中风、精神分裂症、唐氏综合症和麻醉诱发的失忆。因此,一些选择性地指向 α5GABAAR的药理调节剂被作为抑制剂或变构增强剂而发展出来。虽然这些化合物中有许多展示了对上述失调症状的动物模型的治疗作用,但没有一个上市,因为临床试验的失败和人体毒性。这些实验也揭示了α5GABAAR调节的矛盾效果(如:正向和逆向调节都可以治愈认知障碍)。这说明我们对于 α5GABAAR的生理作用的认识是不完全的。这篇综述着重描述了α5GABAAR已被发展出的各种调节剂,关于它们在行为研究中的效果的重要发现,这些研究横跨多个治疗领域的重要性,以及我们对于 α5GABAAR的生理和病理作用的知识缺口。
关键词: 变构调节剂,α5GABAA受体,老年痴呆,健忘症,唐氏综合症,记忆损伤,益智药,中风。
图形摘要
Current Drug Targets
Title:Selective Modulators of α5-Containing GABAA Receptors and their Therapeutic Significance
Volume: 16 Issue: 7
Author(s): Ming Shiuan Soh and Joseph W. Lynch
Affiliation:
关键词: 变构调节剂,α5GABAA受体,老年痴呆,健忘症,唐氏综合症,记忆损伤,益智药,中风。
摘要: GABAA receptors containing the α5 subunit (α5GABAARs) are found mainly in the hippocampus where they mediate a tonic chloride leak current and contribute a slow component to GABAergic inhibitory synaptic currents. Their inhibitory effect on the excitability of hippocampal neurons at least partly explains why changes in the level of activity of α5GABAARs affect cognition, learning and memory. These receptors have been implicated as potential therapeutic targets for a range of clinical conditions including age-related dementia, stroke, schizophrenia, Down syndrome and anesthetic- induced amnesia. Accordingly, a range of pharmacological modulators that selectively target α5GABAARs, as either inhibitors or allosteric enhancers, have been developed. Although many of these compounds show therapeutic effects in animal models of the above clinical disorders, none has been marketed yet due to unsuccessful clinical trials and toxicity in humans. These experiments have also revealed paradoxical effects of α5GABAAR modulation (e.g., cognitive impairments can be reversed by both positive and negative modulation), suggesting that our knowledge of the physiological roles of α5GABAARs is incomplete. This review highlights the various positive and negative modulators for α5GABAARs that have been developed, key findings concerning their effects in behavioral studies, and their importance across a number of therapeutic fields. It also highlights some of the gaps in our knowledge of the physiological and pathological roles of α5GABAARs.
Export Options
About this article
Cite this article as:
Ming Shiuan Soh and Joseph W. Lynch , Selective Modulators of α5-Containing GABAA Receptors and their Therapeutic Significance, Current Drug Targets 2015; 16 (7) . https://dx.doi.org/10.2174/1389450116666150309120235
DOI https://dx.doi.org/10.2174/1389450116666150309120235 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Cognition and Neuropathology in Aging: Multidimensional Perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project
Current Alzheimer Research Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease
Current Psychopharmacology Astrocytic α7 Nicotinic Receptor Activation Inhibits Amyloid-β Aggregation by Upregulating Endogenous αB-crystallin through the PI3K/Akt Signaling Pathway
Current Alzheimer Research Social Markers of Mild Cognitive Impairment: Proportion of Word Counts in Free Conversational Speech
Current Alzheimer Research Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Chemical and Potential Biological Perspectives of Genus Sarcococca (Buxaceae)
The Natural Products Journal Facial Pain Expression in Dementia: A Review of the Experimental and Clinical Evidence
Current Alzheimer Research The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Uric Acid and Cu/Zn Superoxide Dismutase: Potential Strategies and Biomarkers in Functional Recovery of Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets GABAergic Functions and Depression: From Classical Therapies to Herbal Medicine
Current Drug Targets - CNS & Neurological Disorders The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology